Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Advisory Committees Could Get Revamp With A Focus On Science Over Emotion

Executive Summary

CDER Director Cavazzoni also wants to loosen conflict of interest rules and improve technology for remote meetings. Given FDA’s approval of Aduhelm, her comments, made in a prerecorded interview for the BIO Digital annual meeting, may raise some eyebrows. Industry is also working on recommendations for the agency on the topic.

You may also be interested in...



US FDA Could Have Millions Of Advisors, If Not For Current Law, Califf Says

Commissioner Califf says the technology exists and the idea would allow the agency to be more nimble, but the Paperwork Reduction Act makes the process difficult.

Docket Open For OTC Oral Phenylephrine GRASE Meeting, And So Is NDAC Consumer Member Seat

Docket opened for 11-12 September NDAC meeting to consider oral phenylephrine GRASE data available since the agency last examined the ingredient. FDA also accepting nominations for individuals or representatives of consumer organizations for vacancies in voting or non-voting seats across its drug and medical technology advisory committees.

US FDA Looks To Assure Advisory Committees' Subject Expertise With More Temporary Members

Reform efforts in CDER include ensuring expertise is specific to the issues being discussed, which may mean more temporary voting members on advisory committees.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144485

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel